Dr. Tuveson completed his BS in chemistry at M.I.T., an MD-PhD at Johns Hopkins, medical residency at Brigham and Women’s Hospital, and a medical oncology fellowship at Dana-Farber/Harvard. While training, Dr. Tuveson co-developed KIT inhibitors with George Demetri for gastrointestinal stromal tumors, and Kras-dependent mouse cancer models with Dr. Tyler Jacks. At the University of Pennsylvania, his lab generated the first mouse models of ductal pancreatic cancer, and at the University of Cambridge they identified new therapies. At Cold Spring Harbor Laboratory, his lab developed organoid models of pancreatic cancer with Dr. Hans Clevers, enabling basic discoveries and clinical findings including signatures of “common responders” to chemotherapy. Dr. Tuveson is the chief scientist of the Lustgarten Foundation for Pancreatic Cancer Research, Cancer Center director and Roy J. Zuckerberg professor at CSHL, and serves on the Board of Scientific Advisors of the NCI, the Scientific Advisory Committee of SU2C, and the Board of Directors of AACR. His honors include the Rita Allen, Waldenstrom, and Hamdan Awards.